EP3883889A1 - Treatment of skin disorders based on electrolysed water - Google Patents
Treatment of skin disorders based on electrolysed waterInfo
- Publication number
- EP3883889A1 EP3883889A1 EP19813431.4A EP19813431A EP3883889A1 EP 3883889 A1 EP3883889 A1 EP 3883889A1 EP 19813431 A EP19813431 A EP 19813431A EP 3883889 A1 EP3883889 A1 EP 3883889A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- water
- electrolysis
- treatment
- ppm
- mah
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 140
- 238000011282 treatment Methods 0.000 title claims description 37
- 208000017520 skin disease Diseases 0.000 title abstract description 7
- 238000005868 electrolysis reaction Methods 0.000 claims abstract description 57
- 239000000203 mixture Substances 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 32
- 229910052796 boron Inorganic materials 0.000 claims abstract description 26
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims abstract description 25
- 230000008569 process Effects 0.000 claims abstract description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 14
- 229910003460 diamond Inorganic materials 0.000 claims abstract description 12
- 239000010432 diamond Substances 0.000 claims abstract description 12
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229910052710 silicon Inorganic materials 0.000 claims abstract description 10
- 239000010703 silicon Substances 0.000 claims abstract description 10
- 239000000758 substrate Substances 0.000 claims abstract description 9
- 239000011780 sodium chloride Substances 0.000 claims abstract description 7
- 201000004624 Dermatitis Diseases 0.000 claims description 36
- 208000010668 atopic eczema Diseases 0.000 claims description 21
- 239000006071 cream Substances 0.000 claims description 12
- 201000008937 atopic dermatitis Diseases 0.000 claims description 11
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 10
- 239000003995 emulsifying agent Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 238000004064 recycling Methods 0.000 claims description 2
- 230000001143 conditioned effect Effects 0.000 claims 1
- 238000002791 soaking Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000000499 gel Substances 0.000 description 7
- 230000035876 healing Effects 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000000017 hydrogel Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 208000003251 Pruritus Diseases 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 230000007803 itching Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 206010012335 Dependence Diseases 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 239000004927 clay Substances 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 210000003423 ankle Anatomy 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 210000002414 leg Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
- 239000004604 Blowing Agent Substances 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 206010048768 Dermatosis Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000838824 Haliptilon subulatum Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 229960004544 cortisone Drugs 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001823 pruritic effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- RJUMZISZZHYKDC-HZHRSRAPSA-N (e)-n-hydroxy-3-[3-[(4-methoxyphenyl)sulfonyl-propan-2-ylamino]phenyl]-3-pyridin-3-ylprop-2-enamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(C)C)C1=CC=CC(C(=C/C(=O)NO)\C=2C=NC=CC=2)=C1 RJUMZISZZHYKDC-HZHRSRAPSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical class CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- -1 4-methoxybenzenesulfonyl Chemical group 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 150000001638 boron Chemical class 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 210000003467 cheek Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- VYQRBKCKQCRYEE-UHFFFAOYSA-N ctk1a7239 Chemical compound C12=CC=CC=C2N2CC=CC3=NC=CC1=C32 VYQRBKCKQCRYEE-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 238000004050 hot filament vapor deposition Methods 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940124622 immune-modulator drug Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- NXFFJDQHYLNEJK-CYBMUJFWSA-N laropiprant Chemical compound C=1([C@@H](CC(O)=O)CCC=1C=1C=C(F)C=C(C2=1)S(=O)(=O)C)N2CC1=CC=C(Cl)C=C1 NXFFJDQHYLNEJK-CYBMUJFWSA-N 0.000 description 1
- 229950008292 laropiprant Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229910021421 monocrystalline silicon Inorganic materials 0.000 description 1
- HQVFKSDWNYVAQD-UHFFFAOYSA-N n-hydroxyprop-2-enamide Chemical compound ONC(=O)C=C HQVFKSDWNYVAQD-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000004006 olive oil Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 description 1
- 229960005330 pimecrolimus Drugs 0.000 description 1
- 238000000918 plasma mass spectrometry Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/46—Treatment of water, waste water, or sewage by electrochemical methods
- C02F1/461—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
- C02F1/467—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection; by electrooxydation or by electroreduction
- C02F1/4672—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection; by electrooxydation or by electroreduction by electrooxydation
- C02F1/4674—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection; by electrooxydation or by electroreduction by electrooxydation with halogen or compound of halogens, e.g. chlorine, bromine
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/46—Treatment of water, waste water, or sewage by electrochemical methods
- C02F1/461—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/46—Treatment of water, waste water, or sewage by electrochemical methods
- C02F1/461—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
- C02F1/46104—Devices therefor; Their operating or servicing
- C02F1/46109—Electrodes
- C02F2001/46133—Electrodes characterised by the material
- C02F2001/46138—Electrodes comprising a substrate and a coating
- C02F2001/46147—Diamond coating
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2103/00—Nature of the water, waste water, sewage or sludge to be treated
- C02F2103/02—Non-contaminated water, e.g. for industrial water supply
- C02F2103/026—Treating water for medical or cosmetic purposes
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2103/00—Nature of the water, waste water, sewage or sludge to be treated
- C02F2103/42—Nature of the water, waste water, sewage or sludge to be treated from bathing facilities, e.g. swimming pools
Definitions
- the invention relates to the field of treatment of skin conditions such as eczema or atopic dermatitis.
- the invention relates more particularly to a process for obtaining water useful for the treatment of skin conditions comprising an electrolysis treatment.
- the invention also relates to the water obtained by this process, its use for the treatment of said skin conditions by direct application or in the form of compositions, and a suitable device for treating said conditions.
- Eczema which is defined as an inflammation of the skin.
- Eczemas because there are several types, can be allergic or contact or nummular in nature in the form of isolated patches of irritated skin located most often on the arms, buttocks, back or lower legs.
- Atopic dermatitis is a pruritic and inflammatory dermatosis that can be accompanied by asthma, which can spread all over the body in the form of large plaques.
- W0200710766 is cited without being exhaustive.
- the subject of the invention is the use of E-3- [3- [N- (4-methoxybenzenesulfonyl) -N- isopropylamino] phenyl] -3- (3-pyridyl) propenohydroxamic acid of formula (I); or of a pharmaceutically acceptable salt thereof, pharmaceutically acceptable solvents or hydrates, for the preparation of a medicament intended for preventing and / or treating inflammatory skin pathologies, as well as pharmaceutical compositions, in particular dermatological compositions, comprising acid E -3- [3- [N- (4-methoxybenzenesulfonyl) -N-isopropylamino] phenyl-3- (3-pyridyl)
- propenohydroxamic or a pharmaceutically acceptable salt thereof, pharmaceutically acceptable solvents or hydrates, for the treatment and / or prevention of inflammatory skin diseases.
- WO2018041751 which relates to a sulfated polysaccharide extracted from a red alga of the species Haliptilon subulatum, or a salt thereof as an active principle. More particularly, it relates to a sulfated polysaccharide extracted from a red alga of the species Haliptilon subulatum, or a salt thereof as an active principle, for its use in the modulation of the immune response in humans. human or animal, in particular in the prevention and / or treatment of inflammatory diseases, in particular in the skin.
- One of the aims of the invention is therefore to remedy the aforementioned drawbacks and to meet the aforementioned needs by providing electrolyzed water for use in the treatment of inflammatory skin diseases.
- the envisaged use of the electrolyzed water according to the invention is done in the treatment of eczema or atopic dermatitis.
- the electrolyzed water according to the invention is obtained by the implementation of a three-step process which begins with the use of running water or spring water optionally added with sodium chloride (NaCl) at the concentration 0, 5 to 2g / L followed by electrolysis of said water by an electrolysis module comprising at least one diamond electrode doped with boron fixed on silicon substrate in which the boron concentration is between 200 ppm (3x10 19 B atoms / cm 3 ) and 2000 ppm (3.52x10 20 B atoms / cm 3 ), in particular between 200 ppm (3x10 19 B atoms / cm 3 ) and 1500 ppm (2x10 20 B atoms / cm 3 ), the said module submitting the water at an amount of current (current density) during the electrolysis process between 15 and 500 mAh / L of water, more preferably 40 to 250 mAh / L of water, even more preferably 50 to 200 mAh / L, the duration of the electrolysis being less than or equal to 60 minutes and in particular between 15 and
- the electrolysis can be carried out in one continuous or cyclic manner during which the number of cycles is between 2 to 12 times over a 24 hour period and spaced at least half an hour.
- the invention also relates to electrolyzed water obtained by the process described above.
- the invention also relates to a composition comprising an electrolyzed water according to the invention for use as a medicament in the treatment of inflammatory skin diseases.
- the treatment of inflammatory diseases with this composition relates to eczema or atopic dermatitis.
- composition comprising electrolyzed water according to the invention, mainly composed and all or part of water, it consists of 95 to 100% of electrolyzed water and 0 to 5% of an excipient and / or emulsifier.
- composition according to the invention may be in the form of a cream, a gel, a dressing, a patch.
- composition according to the invention for treating skin conditions can consist of a mask that can be applied to the skin or the face, said mask being obtained from a powder such as a clay, an exfoliant, a plant extract in powder or a clay containing activated carbon and added with electrolyzed water obtained according to the process described above.
- composition according to the invention when exclusively composed of electrolyzed water, this can be added to a device containing it.
- Said device being a swimming pool, a spa, a bathtub or a shower.
- the electrolyzed water according to the invention for use in the treatment of inflammatory skin diseases is used over a period ranging from 5 to 60 minutes of exposure.
- the electrolyzed water is obtained thanks to an electrolysis module allowing the implementation of the method described above, said module being if necessary present in a fixed or mobile manner in a device such as a swimming pool, a spa, a bathtub or a shower.
- Figure 1 shows a portion of the ankle of a child suffering from eczema before applying water according to the invention
- Figure 2 shows the ankle portion of Figure 1 five hours after applying the water according to the invention
- Figure 3 shows the ankle portion of Figure 1 two days after applying the water according to the invention
- Figures 1 to 3 show the effectiveness of the electrolyzed water according to the invention in the treatment of eczema on the skin of the feet of a child before treatment and after treatment by bathing in electrolysed water.
- Figure 4 represents the action of a composition according to the invention comprising an electrolyzed water obtained by electrolysis of water by diamond electrodes doped with boron (Electrodes A, 1200 ppm of boron) on silicon substrate on the healing process a wound.
- a composition according to the invention comprising an electrolyzed water obtained by electrolysis of water by diamond electrodes doped with boron (Electrodes A, 1200 ppm of boron) on silicon substrate on the healing process a wound.
- Figure 5 shows a comparative test between a treatment with conventional water (control) and electrolyzed water in a composition according to the invention on the healing process.
- FIG. 6 represents the action of an electrolyzed water obtained by electrolysis of water by diamond electrodes doped with boron (Electrodes B, 2500 ppm of boron) on silicon substrate on the healing process of a wound.
- Eczema is a pruritic dermatosis that manifests itself by a non-contagious inflammation of the skin which is accompanied by redness, fine vesicles, dander and itching. People who have it experience periods when the disease manifests as flares during which symptoms worsen and then subside. These episodes of relapse and lull or remission spread over a more or less long period, especially in adolescents, which can be very disturbing in adolescents.
- the aesthetics of eczema can range from bright red patches spread over a more or less significant part of the body, or appear in the form of pimples. purulent and irritating localized on the face or arms or legs. Beyond the unsightly aspect of these manifestations and the discomfort which results from them, there is pain.
- eczema Among all skin diseases, eczema is the most common: this disease motivates up to 30% of dermatology consultations, reaching 15% to 30% of children and 2% to 10% of adults. Eczema cases have doubled or even tripled in the past 30 years.
- contact or allergic dermatitis which are characterized by lesions of eczema after contact of the skin with certain substances called allergens which can be chemical substances, clothes, sometimes metals.
- allergens can be chemical substances, clothes, sometimes metals.
- Eczema can appear after a few minutes or 3 to 10 days depending on the degree and time of exposure to the allergen.
- the allergic reaction can appear very early in the subject or much later in his life,
- atopic dermatitis characterized by allergic reactions mediated by antibodies called IgE in contact with allergens normally harmless to the rest of the population (dust, pollen, animal hair, etc.).
- allergens normally harmless to the rest of the population (dust, pollen, animal hair, etc.).
- Atopic people often present, simultaneously or alternately, various allergic reactions, such as hay fever, hives, asthma or food allergies.
- lesions appear on the cheeks, forehead and scalp until they extend to the extension faces of the arms and legs and the trunk. They are characterized by dry and rough or oozing and crusty redness, which has the disadvantage of itching and irritation because often lesions of atopic dermatitis will predominate in the bending folds of the elbows and knees or even wrists.
- the lesions are located mainly on the face, neck and limbs. They are often thickened and sometimes purulent.
- Creams or ointments based on corticosteroids are applied to the areas to be treated, which reduces itching and inflammation. Creams and ointments that have a strong steroid effect are used to relieve significant irritation, but over a short period, because in the long term, they lose their effectiveness and can thin the skin.
- Antihistamines are also used against itching, but their action time is limited in time and requires several doses.
- Immunomodulatory drugs are also a remedy against the use of corticosteroids and have the effect of decreasing the activity of the immune system (therefore inflammation) with more or less side effects.
- drugs like Tacrolimus or Pimecrolimus.
- Cyclosporine may be considered. Cyclosporine is an agent of fungal origin which has immunomodulatory properties, it is not devoid of significant side effects on the liver or blood pressure, it can only be used for short periods.
- the present invention concerning a particular electrolyzed water obtained by a process involving particular electrodes of diamond doped with boron fixed on silicon makes it possible to solve the problems or drawbacks previously mentioned. It has the following advantages and improvements:
- the electrolysis module for implementing the method according to the invention in order to prepare the electrolyzed water useful for the treatment of inflammatory skin diseases comprises at least one, preferably at least two boron-doped diamond electrodes which are fixed on a silicon substrate.
- each electrode is between 10 and 100 cm 2 , preferably 60 and 80, more preferably around 70 cm 2 .
- the boron doping of the diamond electrode also has its importance on the properties of the water obtained; the boron concentration is in particular between 200 ppm (3 ⁇ 10 19 B atoms / cm 3 ) and 1500 ppm (2 ⁇ 10 20 B atoms / cm 3 ).
- This boron concentration as well as the nature of the diamond-based electrodes on silicon gives it properties allowing it to operate on a potential between -1V and -2V on the cathodic polarization and on + 2V and + 4V on the anodic polarization. comparison to a platinum reference electrode.
- the electrolysis module is connected to a power supply module and is open to a flow of water which will pass through it.
- the electrodes are supplied with direct current by the power supply module which is connected to the electrolysis module supplying a direct current to said electrode, generally this is fixed between 1 , 5A and 3A. If reverse polarity is required, this can be done automatically by the power module.
- Water can come from different sources but must pass through the electrolysis module without it being able to function in the absence of water.
- the electrolysis module can be permanently traversed by water depending on the device in which it is located.
- An internal measurement or hydraulic flow sensor system is present, interacting with the supply module and which allows the standby, shutdown or start-up of the electrolysis module in the absence or presence of water and therefore to activate electrolysis.
- the water electrolysis module according to the present invention can advantageously operate in automatic mode or can be activated or deactivated on demand, manually or using a remote control system.
- Another advantage of the present invention lies in the fact that the water electrolysis module does not necessarily need permanent activation, but can be usefully activated periodically, that is to say at convenient intervals. , preferably but not necessarily at regular intervals. It has been found that electrolysis of water at regular intervals allows the water to remain therapeutically active for a long time.
- Activating the electrolysis module in order to subject the water to cyclic electrolysis and in which the number of cycles is between 2 to 12 times over a 24 hour period and spaced at least half an hour allows '' obtain water with therapeutic potential.
- the electrolysis module allows the implementation of the process for the preparation of electrolyzed water according to the invention, characterized by the implementation of the following steps. First, running or spring water is supplied, to which optionally a conductivity salt such as sodium chloride (NaCl) is added at a concentration of 0.5 to 2 g / L.
- a conductivity salt such as sodium chloride (NaCl) is added at a concentration of 0.5 to 2 g / L.
- this water is subjected to electrolysis by a device comprising at least one diamond electrode doped with boron fixed on silicon substrate in which the boron concentration is between 200 ppm (3 ⁇ 10 19 B atoms / cm 3 ) and 1500 ppm (2x10 20 B atoms / cm 3 ), the said module subjecting the water to a quantity of the current during the electrolysis process of between 15 and 500 mAh / L of water, more preferably 40 to 250 mAh / L of water, even more preferably 50 to 200 mAh / L, the electrolysis time being between 15 and 60 minutes.
- this electrolysis can be carried out cyclically and the number of cycles is between 2 to 12 times over a 24 hour period and spaced at least half an hour. In the case of a fairly small amount of water used, it can be subjected to a single electrolysis for the period mentioned and between 15 and 30 minutes in the case of unitary or single use.
- An object of the said invention is therefore water as a product obtained by the obtaining process.
- the water thus obtained by the electrolysis process of the invention is suitable for use in the treatment of inflammatory skin diseases and more particularly for use in the treatment of eczema or atopic dermatitis.
- the water thus obtained can be used in different forms or compositions or within different devices.
- the devices used can be selected from a swimming pool, a spa, a bathtub or a water distribution system such as a tap or a shower or an appropriate ambulatory treatment device.
- the electrolysis module used will then be integrated into an existing water circuit in order to prepare the electrolyzed water, for example in swimming pools or spas, or added and connected as a mobile device on a hydraulic circuit in connection with a tap if you consider a shower or a bathtub.
- a electrolysis device and a water tank of determined volume can be connected or assembled in a closed circuit with an applicator member or tap, a recovery device can also be combined so as to avoid losses to the water sewer electrolysed treatment and its recycling to the tank for a new electrolysis.
- the initial water subjected to electrolysis whatever its source, is purified and potentiated by electrolysis. It is therefore not necessary to use distilled water, the electrolysis process of the invention providing an effect as a natural anti-bacterial and fungicide, making it possible to obtain quality water.
- any water whether natural, spring or municipal water can be used in the process for obtaining the electrolyzed water according to the invention.
- the advantage and flexibility of use of the electrolysis module according to the invention makes it possible to obtain, from a common water source, a less expensive treatment since it does not require conventional chemicals in the treatment of inflammatory diseases of the skin, while avoiding the side effects of said chemicals.
- the advantage is that a large area can be treated; it can affect the whole body or all or parts of the body, especially effective when the inflammatory disease is localized in different areas; this avoids using large amounts of cream.
- the treatment can be carried out in a bath for an exposure period ranging from 5 to 45 minutes and repeated more than once a day until the inflammatory symptoms disappear or improve.
- the treatment is more effective after two days and from 5 hours after exposure for fifteen minutes in a bath comprising the electrolysed water according to the method of the invention.
- a very high density of inflammation of the skin is observed in the foot, which subsides 5 hours after exposure in the bath, then two days after the bath, the inflammatory part appears be in the form of a crust still reddish but no longer causing itching conducive to forming crusts which will fade later.
- the electrolyzed water obtained by the process according to the invention, can also be present in more conventional compositions which are encountered on sale in pharmacies or parapharmacies or even large areas, said composition comprising 95 to 100% of electrolyzed water and 0 to 5% of an excipient and / or emulsifier.
- composition for use as a medicament in the treatment of inflammatory skin diseases more particularly eczema or atopic dermatitis.
- It can be in the form of a cream, gel, dressing, patch.
- the excipients and / or natural or synthetic emulsifiers selected from petrolatum, glycerin, paraffin, cetearyl glucose, beeswax or rice wax, soya lecithin, esters of sugar, glyceryl stearate, olive oil derivatives or a mixture of these.
- Another galenical form which can be used of the composition according to the invention for treating skin conditions can consist of a mask which can be applied to the skin or the face, said mask being obtained from a powder such as a clay, an exfoliant. , a plant extract in powder or a clay containing activated carbon and added with electrolyzed water obtained according to the process described above.
- a person skilled in the art will know how to adapt the ratio between powder and electrolyzed water according to the invention in order to obtain the consistency of the mask desired.
- oil in water also called O / W
- the amount of water is greater than the amount of oil.
- This type of emulsion is nourishing and hydrating. It is ideally used to make day creams, body milks, it can also be integrated into patches or adhesives of the dressing type.
- a hydrogel is a gel in which the blowing agent is water.
- the matrix of a hydrogel is generally a network of polymers which are insoluble in water, but are capable of swelling substantially in the presence of a large amount of water or aqueous solutions.
- compositions according to the invention may be possible depending on the needs of the patient to be treated and the extent of the inflammation process. It can be in the form of a cream, gel or emulsion or in the form of a dressing-type adhesive or a skin patch.
- the composition according to the invention in the case of a composition called O / W (oil in water) comprises from 95 to 100% of electrolyzed water and from 0 to 5% of an excipient and / or emulsifier.
- the electrolyzed water is not the majority compound; this is the case of a composition called W / O (water in oil), said composition comprises from 70 to 90% of an excipient and / or emulsifier from 10 to 30% by weight of electrolysed water.
- a hydrogel is a gel in which the blowing agent is water.
- the matrix of a hydrogel is generally a network of polymers which are insoluble in water, but are capable of swelling substantially in the presence of a large amount of water or aqueous solutions.
- the boron-doped electrodes (hereinafter designated BDD / Si electrodes) used in this experiment have the following characteristics:
- BDD / Si electrodes diamond film doped with boron on silicon substrate: Substrate: monocrystalline silicon (100), resistivity 100 mohm.cm
- - BDD film polycrystalline, thickness ⁇ 2-3pm, doping 1200 ppm of boron (Electrode A) or 2500 ppm of boron (Electrode B),
- the electrodes A and B were manufactured according to the same diamond film growth protocol in an HF-CVD machine (Hot Filament Chemical Vapor Deposition. They are identical in all respects and differ only in their respective boron content.
- HF-CVD machine Hot Filament Chemical Vapor Deposition. They are identical in all respects and differ only in their respective boron content.
- the protocol of implementation of the electrodes on the culture water is as follows:
- a 2.5 L tank contains city water at 15 ° C. This water is pumped at a fixed flow rate of 200 L / h through an electrolysis module and then returned to the tank, therefore in a closed circuit.
- the electrolysis module implements 2 electrodes spaced 1 mm and 70 cm 2 of active surface.
- the water in the tank is kept at a constant temperature of 20 ° C during the test.
- the culture protocol is as follows:
- Fibroblasts L-929 (mouse fibroblasts; ACC 173; DSMZ); internal passage P52-53; recommended according to EN ISO 10993-5: 2009).
- the cells are incubated and cultured en masse in an incubator at 37 ° C with a controlled closed environment containing 5% CO 2 and 95% air.
- the culture medium is RPMI 1640 with 10% physiological bovine serum, 100 Unit / ml of penicillin and 100 ⁇ g / ml of streptomycin.
- the protocol for studying cell regeneration / healing is as follows:
- silicone culture inserts ibidi GmbH, Oberkoch.
- this insert When this insert is placed in a culture medium, it constitutes 2 culture tanks separated by a wall 500 ⁇ m thick. The cells are cultured in the two tanks and the silicone insert is removed. This makes it possible to obtain two perfectly defined culture patches spaced precisely 500 ⁇ m apart.
- cells type L-929 were obtained from 80 to 90% by mass of suspension cultures with a density of 500,000 cells / ml. 100 ⁇ L of suspension are introduced into each culture insert reservoir. The cells are cultured for 24 hours in order to obtain homogeneous populations in each of the two reservoirs of each insert. Then, the insert is gently removed, revealing a free space of 500 ⁇ m separating the two culture media. The electrolyzed water is injected up to 500 pL for 1.500 pL of fresh culture medium (dilution 1: 4). The culture media are cultured again for 24 hours. Then, layers of cells were fixed by methanol treatment for 2 min and colored with a Coomassie-Giemsa solution according to Romanowsky.
- the protocol for tap water electrolysis is as follows:
- the water used is city water.
- the electrolysis protocol is as follows: City water is pumped at a flow rate of 90 L / h through an electrolysis module equipped with 2 BDD A electrodes as defined in Example 1 (1200 ppm B) spaced 1 mm apart, having 12.5 cm 2 of active surface.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Electrochemistry (AREA)
- Water Supply & Treatment (AREA)
- Environmental & Geological Engineering (AREA)
- Hydrology & Water Resources (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Water Treatment By Electricity Or Magnetism (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1871657A FR3088543B1 (en) | 2018-11-21 | 2018-11-21 | Treatment of skin conditions with electrolyzed water |
PCT/EP2019/082163 WO2020104630A1 (en) | 2018-11-21 | 2019-11-21 | Treatment of skin disorders based on electrolysed water |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3883889A1 true EP3883889A1 (en) | 2021-09-29 |
Family
ID=66641014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19813431.4A Pending EP3883889A1 (en) | 2018-11-21 | 2019-11-21 | Treatment of skin disorders based on electrolysed water |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210403347A1 (en) |
EP (1) | EP3883889A1 (en) |
JP (1) | JP2022507794A (en) |
CN (1) | CN113316561A (en) |
AU (1) | AU2019382893A1 (en) |
BR (1) | BR112021009675A8 (en) |
EA (1) | EA202191297A1 (en) |
FR (1) | FR3088543B1 (en) |
IL (1) | IL283263A (en) |
WO (1) | WO2020104630A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11655163B2 (en) | 2020-05-19 | 2023-05-23 | Waterdiam Group Llc | Clean water for bathing and medical treatments |
FR3140872A1 (en) * | 2022-10-18 | 2024-04-19 | Weo Llc. | Water bottle comprising a water function augmentation device |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09268395A (en) * | 1996-04-02 | 1997-10-14 | Permelec Electrode Ltd | Electrode for electrolysis and electrolytic cell using this electrode |
JPH11332944A (en) * | 1998-05-22 | 1999-12-07 | Kazuyuki Kaneko | Treatment of dermatitis and apparatus therefor |
JP4811844B2 (en) * | 2003-11-11 | 2011-11-09 | ペルメレック電極株式会社 | Method for producing percarbonate |
JP4410155B2 (en) * | 2005-06-16 | 2010-02-03 | ペルメレック電極株式会社 | Electrolyzed water ejection device |
CN101223016B (en) | 2005-07-15 | 2012-02-29 | 东洋橡胶工业株式会社 | Manufacturing method of laminated sheet and laminated sheet |
JP4903405B2 (en) * | 2005-08-10 | 2012-03-28 | 東海旅客鉄道株式会社 | Ozone water generation method and ozone water generation apparatus |
JP2009523832A (en) * | 2006-01-20 | 2009-06-25 | オキュラス イノヴェイティヴ サイエンシズ、インコーポレイテッド | Method for treating or preventing peritonitis using redox potential aqueous solution |
US8273225B2 (en) * | 2006-09-05 | 2012-09-25 | Element Six Limited | Solid electrode |
JP5098050B2 (en) * | 2006-11-16 | 2012-12-12 | ペルメレック電極株式会社 | Membrane-electrode assembly, electrolysis unit using the same, electrolyzed water ejection device, and sterilization method |
JP5690587B2 (en) * | 2007-04-25 | 2015-03-25 | アペエール ナノテクノロジーズ ソシエテ アノニム | Highly stable electrolyzed water with reduced NMR half-width |
JP5582711B2 (en) * | 2008-09-25 | 2014-09-03 | 株式会社エー・アイ・システムプロダクト | Lotion |
CH706747A2 (en) * | 2012-07-17 | 2014-01-31 | Hanspeter Steffen | Process for hydration, tightening and care of the skin, for the treatment of dermatoses, sunburn and general wounds with electrolysis water produced with diamond electrodes. |
FR3000399B1 (en) | 2012-12-31 | 2015-03-27 | Galderma Res & Dev | TOPICAL USE OF LAROPIPRANT FOR THE TREATMENT OF ROSACEA |
AT514092B1 (en) * | 2013-02-21 | 2015-02-15 | Pro Aqua Diamantelektroden Produktion Gmbh & Co Kg | Use of electrolysis water and methods for preventing or obstructing as well as for reducing spore germination and mycelial growth of fungi of the genera Botrytis and Fusarium |
FR3051206B1 (en) * | 2016-05-10 | 2020-06-12 | Waterdiam France | WATER TREATMENT AND DISTRIBUTION DEVICE FOR A FARM |
GB2551692B (en) * | 2016-05-20 | 2020-12-09 | Ozo Innovations Ltd | Electrolyzed water composition |
FR3055550B1 (en) | 2016-09-02 | 2019-06-28 | Sigma Clermont | NOVEL ACTIVE IMMUNOMODULATOR AND COMPOSITION COMPRISING SAME |
WO2019166844A1 (en) * | 2018-02-28 | 2019-09-06 | Waterdiam France | Electrolysis method and device for spas and pools |
-
2018
- 2018-11-21 FR FR1871657A patent/FR3088543B1/en active Active
-
2019
- 2019-11-21 BR BR112021009675A patent/BR112021009675A8/en not_active Application Discontinuation
- 2019-11-21 AU AU2019382893A patent/AU2019382893A1/en active Pending
- 2019-11-21 EA EA202191297A patent/EA202191297A1/en unknown
- 2019-11-21 JP JP2021527865A patent/JP2022507794A/en active Pending
- 2019-11-21 CN CN201980081317.3A patent/CN113316561A/en active Pending
- 2019-11-21 WO PCT/EP2019/082163 patent/WO2020104630A1/en unknown
- 2019-11-21 EP EP19813431.4A patent/EP3883889A1/en active Pending
- 2019-11-21 US US17/296,096 patent/US20210403347A1/en active Pending
-
2021
- 2021-05-19 IL IL283263A patent/IL283263A/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022507794A (en) | 2022-01-18 |
BR112021009675A2 (en) | 2021-08-24 |
BR112021009675A8 (en) | 2022-11-29 |
CN113316561A (en) | 2021-08-27 |
EA202191297A1 (en) | 2021-09-10 |
WO2020104630A1 (en) | 2020-05-28 |
FR3088543A1 (en) | 2020-05-22 |
FR3088543B1 (en) | 2021-03-19 |
IL283263A (en) | 2021-07-29 |
AU2019382893A1 (en) | 2021-06-24 |
US20210403347A1 (en) | 2021-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2363019T3 (en) | USE OF PIRLINDOL FOR THE TREATMENT OF DISEASES THAT ARE CHARACTERIZED BY A PROLIFERATION OF T-LYMPHOCYTES AND / OR HYPERPROLIFERATION OF KERATINOCITS IN PARTICULATE AOPHIC DERMATITIS AND PSORIASIS. | |
KR20080043763A (en) | Treatment of inflammatory conditions | |
FR2847267A1 (en) | METHOD FOR TESTING THE ACTIVITY OF A POTENTIALLY ACTIVE SUBSTANCE TO INHIBIT THE ENZYMATIC ACTIVITY OF PHOSPHOLIPASE A2 | |
WO2001037799A1 (en) | Ajuga turkestanica extract and its cosmetic uses | |
EP2266530B1 (en) | Oxazolidinones for cosmetic cutaneous use | |
EP3393488B1 (en) | Composition comprising an ambora extract and a green tea extract for the treatment of psoriasis, atopic dermatitis, chronic urticaria, antihistamine-resistant pruritus and senile pruritus | |
EP2364135B1 (en) | Drug or dermatological composition containing an avocado peptide extract for treating and preventing intern pruritus | |
EP3883583B1 (en) | Healing composition comprising electrolyzed water | |
WO2020104630A1 (en) | Treatment of skin disorders based on electrolysed water | |
EP2986347B1 (en) | Cosmetic applications of lactobacillus pentosus | |
FR3000896A1 (en) | GALENIC FORM FOR ADMINISTRATION OF ACTIVE INGREDIENT (S) FOR ACCELERATED INDUCTION OF SLEEP AND / OR TREATMENT OF SLEEP DISORDERS | |
Gadzhigoroeva et al. | COVID-19 can exacerbate pattern hair loss and trigger telogen effluvium-the role of proteoglycan replacement therapy with nourkrin® in clinical treatment of covid-19 associated hair loss | |
EP1458347B1 (en) | Composition comprising at least an alkanolamide for inhibiting langerhans cell migration, and uses thereof | |
WO2019092264A1 (en) | Use of 4-(1-phenylethyl)benzene-1,3-diol in the treatment of inflammatory dermatoses | |
EP3946378A1 (en) | Dextran sulfate for inflammatory skin conditions | |
RU2571072C1 (en) | Agent for treating and preventing itching dermatosis | |
JP7396585B2 (en) | Composition for suppressing TSLP gene expression, suppressing IL-33 gene expression, or promoting filaggrin production | |
JP2005298504A (en) | Skin lotion composition containing saccharide isomerate and ginkgo leaf extract | |
Ashara et al. | Association of permeability and lipid content of membrane | |
WO2023180981A1 (en) | Melaleuca alternifolia extract and cosmetic uses thereof | |
EP3766505B1 (en) | Treatment of skin lesions associated with autoimmune and inflammatory diseases using the as2o5 arsenic compound | |
BE1027772A1 (en) | COMPOSITION OF GINSENG TO IMPROVE SKIN CONDITION AND ITS USE FOR THE TREATMENT OF DERMATOLOGICAL DISEASES | |
FR3088824A1 (en) | LOW MOLECULAR WEIGHT SULPHATE FUCANES IN INFLAMMATORY DERMATOSIS | |
FR3065372A1 (en) | COMPOSITION COMPRISING CARBOXY METHYL NARINGENINE CHALCONE FOR THE TREATMENT OF PRURIT AND ATOPIC DERMATITIS | |
FR3065373A1 (en) | COMPOSITION COMPRISING COGNASSIER EXTRACT FOR THE TREATMENT OF PRURIT AND ATOPIC DERMATITIS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210512 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: WEO, LLC |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230515 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20240125 |